DUVA Introduces DUVA ONE at IFA 2026: Personalized Sleep Earbuds That Respond in Real Time

The Sleep System That Understands You Best.

BERLIN, Sept. 6, 2026 /PRNewswire/ -- DUVA, created by Fitnexa, is introducing DUVA ONE at IFA Berlin 2026. This intelligent in-ear sleep system is designed to sense changes in the user and the bedroom, then personalize audio, noise control, and device behavior throughout the night.

Most sleep wearables explain what happened after users wake up. DUVA ONE is designed to help while the night is still happening. Its low-profile earbuds, environment-sensing charging case, and app work together to determine when and how to respond.

A user might start the night with a podcast over Bluetooth. After they fall asleep, DUVA ONE can introduce locally stored sleep audio and optimize power use. If a partner begins snoring or traffic grows louder, it can adjust ANC or add sound masking. In the morning, a private offline alarm wakes only the wearer, without requiring an active phone connection.

In-ear PPG and motion sensors estimate sleep stages and track heart rate, HRV, sleep position, and movement, while the case monitors noise, light, temperature, and humidity. The AI Agent interprets these signals alongside playback status and personal preferences to select an appropriate response. Users control sleep audio, playback duration, ANC strategy, and nighttime interventions in the DUVA App.

"Sleep does not happen in a static environment, so sleep technology should not remain static either," said Diego, Founder of Fitnexa. "DUVA ONE is designed to respond while sleep is still happening."

- Layered noise relief: Passive isolation, Hybrid ANC, and sleep audio provide noise reduction of up to 42 dB, with Transparency Mode and adaptive ANC calibration.

- Personalized AI sleep guidance: The AI analyzes the user's real-time sleep state and generates personalized audio guidance to help them gradually fall asleep.

- Side-sleeping comfort: Each fitted earbud weighs approximately 3.3 grams and has an approximately 9.9 mm low-profile design. Two ear-tip shapes and multiple tip and stabilizing-wing sizes provide more than 40 fit configurations.

- All-night battery: Up to 16 hours in the most power-efficient configuration, including 13 hours of local audio with ANC off and 9.5 hours with ANC on. The USB-C and wireless charging case provides up to five additional recharges.

- Private offline alarm: Alarms gradually increase in volume and offer 5, 10, or 15-minute snooze options through the earbud controls.

- Privacy-first sensing: DUVA ONE does not record conversations, store ambient audio, or upload raw environmental audio. Users can disable individual sensors and delete historical data.

DUVA ONE is planned for release in October 2026 at a target retail price of US$349.99, with target markets including the United States, Canada, the United Kingdom, the European Union, and Australia.

Media Contact: [email protected]

Learn more: duva.com

Share this article

New Circles analysis finds price and network quality remain the foundations of retention, while bundles, rewards and personalization must prove their impact on customer loyalty

SINGAPORE, Sept. 6, 2026 /PRNewswire/ -- More than half (53%) of consumers across five of Europe's largest telecommunications markets – France, Germany, Italy, Spain and the United Kingdom – are open to switching mobile providers, highlighting growing pressure on traditional approaches to customer loyalty, according to new analysis from Circles.

The new Consumer Insights: Customer Stickiness & Loyalty in European Telecommunications report brings together country-level consumer and market data from across Europe to examine what is driving switching intention, which retention levers still matter and why operators need strategies tailored to different markets and customer segments.

The findings reveal a fragmented loyalty landscape across Europe. Switching behavior varies considerably by market, age, customer value and exposure to low-cost competition, making a standardized pan-European retention strategy increasingly difficult to justify.

Europe Does Not Have One Loyalty Problem

The analysis identifies sharp differences across major European markets:

- Germany: The generational divide is particularly pronounced. Earlier European consumer research found that 64% of adults under 35 were open to switching, while 75% of consumers over 55 intended to remain with their provider.

- Italy: Two-year mobile switching intention increased from 18% in 2023 to 27% in 2024, the largest year-on-year increase among the five markets studied – with low-cost operators proving particularly attractive to potential switchers.

- United Kingdom: 31% of respondents said they were likely to change mobile operator within two years in 2024, six percentage points higher than in 2023.

- Spain: Despite a highly converged fixed-mobile market, consumers continue to move towards low-cost alternatives. Approximately 55% of the intended destinations among switchers were low-cost operators, suggesting that bundle ownership alone does not guarantee loyalty.

Price and Network Quality Still Define the Core Proposition

Across the five markets, price remains the leading factor when consumers consider a new provider, followed by network speed, signal coverage, service reliability and handset discounts.

The findings reinforce that loyalty initiatives cannot compensate for weaknesses in the core customer proposition. Rewards and personalization can strengthen retention, but competitive pricing and dependable connectivity remain its foundation.

"What this research makes clear is that European telcos are not facing just one loyalty problem, but a different one in every market. While price and network quality remain the price of entry, they no longer explain who stays and who leaves. The real differentiator is whether an operator understands what a specific customer values and can act on it. After all, bundles, rewards and personalized offers only build loyalty if it's relevant to that customer, not just available to them. At Circles, we have partnered operators globally to move from generic retention programs to ones that are tested against real customer value. The operators who get this right will not just reduce churn; they will set the standard for what loyalty means in an increasingly converged, commoditized market," said Rameez Ansar, Co-Founder & CEO at Circles.

Bundles Do Not Automatically Create Loyalty

The report also challenges a long-standing assumption that combining fixed and mobile services automatically locks in customers. In the UK, Italy and Germany, fewer than 43% of consumers hold both services with the same operator, and consumer research indicates that convergence has not reliably prevented mobile churn. Even in highly converged markets such as Spain, low-cost competition and the commoditization of bundles are putting pressure on traditional retention models.

Circles recommends that operators measure convergence by what it actually delivers: lower churn, stronger satisfaction, higher profitability and greater customer lifetime value. Bundle penetration, on its own, should not be treated as proof of loyalty.

The Next Battleground: Relevant Customer Value

Network quality remains critical, but in mature markets, incremental improvements can become harder for mainstream consumers to perceive. Deloitte's 2026 TMT prediction on mobile loyalty suggests that rewards are already the leading non-price switching consideration in the Netherlands and Belgium and the second-ranked consideration in the UK.

The opportunity is not to add more generic perks. It is to deliver value that is visible and relevant to a particular customer, including pricing transparency, useful rewards, service recovery, entertainment or device benefits, household convenience and personalized treatment. Circles says these interventions should be targeted and tested against measurable retention and customer-value outcomes.

Four Priorities for European Operators

Based on the analysis, Circles identifies four priorities for operators seeking to strengthen customer loyalty:

- Defend the core proposition first – competitive pricing, network quality and reliability remain fundamental.

- Segment retention strategies by market, demographics and customer value rather than applying a single loyalty model.

- Measure what actually works by assessing the impact of bundles, rewards and personalization on churn, profitability and customer lifetime value.

- Respond differently to low-cost competition in each market, reflecting local customer behaviour and competitive dynamics.

Circles brings an operator's perspective to the challenge through its experience building and operating digital telco brands and its AI-enabled SaaS capabilities. The company says the opportunity for European telcos is to connect a 360-degree understanding of customers with the operational agility to adapt propositions, experiences and interventions continuously.

Read the full report: Consumer Insights: Customer Stickiness & Loyalty in European Telecommunications

About Circles

Founded in 2014, Circles is a global technology company reimagining the telco industry with its innovative SaaS platform, empowering telco operators worldwide to effortlessly launch innovative digital brands or refresh existing ones, accelerating their transformation into techcos.

Today, Circles partners with leading telco operators across 14 countries and 6 continents, including KDDI Corporation, Etisalat Group (e&), AT&T, and Telkomsel, creating blueprints for future telco and digital experiences enjoyed by millions of consumers globally.

Circles is backed by renowned global investors, including Peak XV Partners (formerly Sequoia), Warburg Pincus, Founders Fund, and EDBI (the investment arm of the Singapore Economic Development Board), with a track record of backing industry challengers.

To learn more about how Circles enables digital transformation for leading telcos worldwide, visit circles.co.

SOURCE Circles.co

Share this article

Interim MASTRR Registry analysis represents, to Aroa's knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstruction

AUCKLAND, New Zealand, Sept. 6, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX: ARX), a soft tissue regeneration company, today announced the peer-reviewed publication of interim results from its ongoing MASTRR Registry, reporting low infection rates and no adverse events definitely related to Myriad products.

Published in Advances in Therapy, the interim analysis included 411 patients and 474 soft tissue defects treated across 10 US centers. To Aroa's knowledge, it is the largest published prospective analysis of a bioscaffold in in-patient soft tissue reconstruction.

Myriad Matrix™ and Myriad Morcells™ were evaluated across a broad range of complex soft tissue reconstruction procedures in a highly challenging real-world patient population. Approximately 59% of patients were ASA Class III or IV, indicating significant underlying systemic disease. In addition, 35% had diabetes, 30% had vascular disease and 23% used nicotine. The defects were similarly complex, with approximately 89% clean-contaminated or contaminated, 59% chronic, 15% involving confirmed osteomyelitis and 11% involving exposed structures, including bone, tendon or viscera.

Despite this complexity, deep tissue infection occurred in only 0.7% of patients and superficial infection in 2.9%. No infections were attributed to Myriad over a median follow-up period of 27 weeks. Across the 474 defects, the median number of Myriad applications was one.

Aroa CEO Brian Ward said the publication marks an important milestone for Myriad and the MASTRR Registry.

"This is an important milestone for Myriad and the MASTRR Registry. AROA is lifting the bar for the quality of clinical evidence in soft tissue reconstruction," Mr Ward said.

"As the largest published prospective analysis of a bioscaffold in this field that we are aware of, the study provides a substantial dataset encompassing 411 patients and 474 complex soft tissue defects.

"Despite the challenging patient population, infection rates were exceptionally low, and no adverse events were causally related to Myriad. It is also encouraging to see the authors note the infection profile compared very favourably with other commercially available bioscaffolds, as we see this as a key differentiator."

The authors of the interim analysis discussed Myriad's low infection rates in the context of infection rates reported for several resorbable synthetic bioscaffold products used in complex soft tissue reconstruction, as reported in separately published meta-analyses. Those reported infection rates ranged from 16% to 25%.

Post-operative infections can delay healing, increase the risk of further complications and may require additional treatments, surgical interventions or hospitalization. A large US analysis of patients undergoing open surgical procedures found that a surgical site infection added an average 7.8–9.3 days to a patient's hospital stay and approximately US$18,600–US$21,000 in healthcare costs, with deep tissue infections creating an even greater burden.[1]

While the MASTRR interim analysis assessed safety rather than healthcare utilization or cost savings, Aroa said Myriad's favourable infection profile may be relevant to healthcare providers managing complex soft tissue defects.

The MASTRR Registry is an ongoing prospective, multicenter observational study evaluating the real-world safety and performance of Myriad Matrix and Myriad Morcells. More than 550 patients are currently enrolled, and the registry is approved to enroll up to 800 patients across 15 US sites.

The publication adds to previously published procedure-specific analyses from the MASTRR Registry in lower extremity reconstruction, trauma, burns, pilonidal disease and pressure injuries. Aroa expects the expanding registry dataset to support further analyses across multiple surgical specialties and applications.

Aroa said the findings support the growing body of clinical evidence for Myriad and build on the product's strong commercial momentum, following 54% sales growth in FY26.

The study, Safety of Ovine Forestomach Matrix Across 474 Soft Tissue Defects: Interim Results from the Prospective Multicenter MASTRR Registry, has been published in Advances in Therapy and is available online here

About AROA

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'.

We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix bioscaffold derived from ovine (sheep) forestomach.

Over 7.5 million AROA devices have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELABio, Inc.

Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com

SOURCE Aroa Biosurgery

Share this article

Baidu Announces Inclusion of Its Class A Ordinary Shares in the Shenzhen-Hong Kong Stock Connect and Shanghai-Hong Kong Stock Connect Programs

BEIJING, Sept. 6, 2026 /PRNewswire/ -- Baidu, Inc. ("Baidu" or the "Company") (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)), a leading AI company with strong Internet foundation, today announced that the Company's Class A ordinary shares traded on The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") have been included in the Shenzhen-Hong Kong Stock Connect program, effective today, September 7, 2026 (Beijing time). The previously announced inclusion of the Company's Class A ordinary shares in the Shanghai-Hong Kong Stock Connect program also became effective today. Eligible investors in the Chinese Mainland now have direct access to the trading of Baidu's Class A ordinary shares through both programs.

The inclusion of Baidu's Class A ordinary shares in the Shenzhen-Hong Kong Stock Connect program is pursuant to the Announcement on Adjustment of the List of the Eligible Stocks in Hong Kong Stock Connect under the Shenzhen-Hong Kong Stock Connect issued by the Shenzhen Stock Exchange on September 7, 2026.

Taken together, the inclusion in the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect marks an important step toward expanding the Company's reach among Chinese Mainland investors and is expected to further diversify its investor base and enhance the liquidity of its shares.

Baidu appreciates the continued support of its shareholders and investors and remains committed to driving sustainable growth and creating long-term value for shareholders.

About the Shenzhen-Hong Kong Stock Connect

The Shenzhen-Hong Kong Stock Connect is a mutual stock market access mechanism between the Chinese Mainland and Hong Kong under which the Shenzhen Stock Exchange and the Hong Kong Stock Exchange have established technical connectivity to enable investors in the Chinese Mainland and Hong Kong to trade eligible shares listed on the other's market through their local securities companies or brokers.

About the Shanghai-Hong Kong Stock Connect

The Shanghai-Hong Kong Stock Connect established a two-way trading link between the Shanghai Stock Exchange and the Hong Kong Stock Exchange. The stock connect allows qualified Chinese Mainland investors to access eligible Hong Kong shares (Southbound) as well as Hong Kong and overseas investors to trade eligible A-shares (Northbound), subject to a certain amount of daily quota.

About Baidu

Founded in 2000, Baidu's mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on Nasdaq under "BIDU" and HKEX under "9888". One Baidu ADS represents eight Class A ordinary shares.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, Baidu's and other parties' strategic and operational plans, contain forward-looking statements. Baidu may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in announcements made on the website of the Hong Kong Stock Exchange, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Baidu's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Baidu's growth strategies; its future business development, including development of new products and services; its ability to attract and retain users and customers; competition in the Chinese Internet search and newsfeed market; competition for online marketing customers; changes in the Company's revenues and certain cost or expense items as a percentage of its revenues; the outcome of ongoing, or any future, litigation or arbitration, including those relating to intellectual property rights; the expected growth of the Chinese-language Internet search and newsfeed market and the number of Internet and broadband users in China; Chinese governmental policies relating to the Internet and Internet search providers, and general economic conditions in China and elsewhere. Further information regarding these and other risks is included in the Company's annual report on Form 20-F and other documents filed with the Securities and Exchange Commission, and announcements on the website of the Hong Kong Stock Exchange. Baidu does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release and in the attachments is as of the date of the press release, and Baidu undertakes no duty to update such information, except as required under applicable law.

SOURCE Baidu, Inc.

Share this article

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Sept. 6, 2026 /PRNewswire/ -- Today, shares of Harbour BioMed (the "Company"; HKEX: 02142.HK) were officially included in the eligible shares list of the Stock Connect. Effective immediately, qualified investors in mainland China can directly invest in the Company's shares through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs.

This inclusion in Stock Connect marks a significant milestone, reflecting that the Company's market capitalization has steadily surpassed the HK$10 billion threshold, officially positioning it among the large- and mid-cap biopharmaceutical companies in the Hong Kong stock market. This achievement underscores the capital market's positive recognition of the Company's growth prospects, R&D momentum, and strategic execution, while also serving as a strong testament to its long-term value being steadily acknowledged in the secondary market.

In the first half of 2026, the Company recorded total revenue of approximately US$122.5 million, representing a year-over-year increase of 20.9%. Adjusted net profit reached approximately US$71.6 million, marking seven consecutive profitable half-years and confirming that Harbour BioMed has officially entered a phase of "normalized profitability," further validating the sustainability and replicability of the business model underpinning this platform-based biopharmaceutical group. Cash and cash equivalents stood at approximately US$359.2 million as of June 30, 2026. The Company maintains strong financial resources and flexibility to support its strategic execution.

In terms of the pipeline, the Company has built a portfolio of nearly 30 differentiated drug candidates across multiple therapeutic areas, including immunology, oncology, metabolism, and the central nervous system (CNS), with several molecules having already entered clinical trials or regulatory submission stages. Batoclimab (HBM9161), the Company's lead asset, has been submitted for Biologics License Application (BLA) review and is positioned as a potential blockbuster therapy for multiple autoimmune indications. Porustobart (HBM4003), the first fully human heavy-chain-only antibody which entered clinical development globally, has demonstrated positive efficacy and safety profiles in multiple monotherapy and combination studies targeting advanced solid tumors. HBM9378, a next-generation ultra-long-acting anti-TSLP monoclonal antibody, has recently achieved several key milestones. Our partner, Windward Bio, has initiated the Phase II SIRIUS study for HBM9378 for the treatment of COPD and completed dosing of the first patients. Meanwhile, initial readouts from the Phase II/III POLARIS study in asthma are expected in the second half of 2026, with the first Phase III study of HBM9378 in asthma is expected to begin in the fourth quarter of 2026.

Additionally, continued progress on innovative molecules such as HBM7575, HBM7020, and LET003 underscores the Company's capabilities in target selection and molecular design.

To date, the Company has propelled its core pipeline into the global market through a series of out-licensing transactions. Notable examples include the out-licensing of ex-China rights for HBM9378 to Windward Bio; an ex-China licensing agreement for HBM7020 (BCMA×CD3) with Otsuka Pharmaceutical; a license agreement and equity partnership with Solstice Oncology for HBM4003; and a licensing and collaboration agreement with AstraZeneca for HBM7022 (Claudin18.2×CD3). These partnerships strongly demonstrate the Company's strategic execution capabilities in unlocking the global value of its pipeline and accelerating clinical translation through flexible and diversified collaboration models.

Leveraging its industry-leading Harbour Mice® fully human antibody technology platform, Harbour BioMed has established itself as a leading force in biotech BD partnerships. Its subsidiary, Nona Biosciences, has further built out four major technology engines—a bispecific/multispecific antibody platform, an XDC platform, a CAR-T platform, and an AI-driven drug discovery platform—giving it a foundational edge in the ongoing innovation wave that is moving the field from antibodies to antibody-plus, and from simple molecules to complex modalities.

To date, the Company has entered into long-term strategic partnerships with leading multinational pharmaceutical companies, including AstraZeneca, Otsuka Pharmaceutical, Bristol Myers Squibb (BMS), and Pfizer, with cumulative global collaboration deal value exceeding US$13 billion. The partnership with AstraZeneca stands out as a particularly representative example: the relationship has evolved from a single-product license into a multi-dimensional framework encompassing R&D collaboration, equity investment, and a joint laboratory initiative—marking a significant value leap from product-level licensing to platform-level strategic partnership. This collaboration serves as a benchmark paradigm for how innovative biotechnology companies in China can establish deep, strategic collaborations with top-tier multinational companies (MNCs).

Meanwhile, the Company has been actively driving the deep integration of AI into drug R&D. In October 2025, Harbour BioMed unveiled its first fully human AI HCAb generation and screening model powered by the Hu-mAtrIx™ platform, establishing a closed loop of "AI design – intelligent screening – wet-lab validation" that significantly enhances the efficiency and precision of antibody discovery. In 2026, LET003, a next-generation anti-ACVR2A/2B monoclonal antibody developed using the Hu-mAtrIx™ platform, delivered superior preclinical data. Subsequently, the Company entered into a strategic collaboration with BioMap to co-found MegaStream TechBio, integrating a proprietary ecosystem of exclusive datasets × purpose-built large models × large-scale innovative pipeline portfolio into an AI-powered R&D engine.

This inclusion in the Stock Connect program will further broaden the Company's investor base, attract greater participation from southbound capital, effectively enhance stock liquidity and market visibility, and facilitate a more comprehensive discovery and recognition of the Company's value in the capital markets. Besides, a more diversified investor composition will further strengthen the Company's presence in the international capital markets, fostering a more stable and dynamic capital ecosystem to support its long-term growth.

Dr. Jingsong Wang, Founder, Chairman, and Chief Executive Officer of Harbour BioMed, commented: "The inclusion of our shares in the Stock Connect program marks an important capital markets milestone for Harbour BioMed. It strongly reflects the market's recognition of our business momentum, innovation capabilities, and corporate governance, while also positioning us to attract greater interest and support from long-term value investors. Going forward, we remain steadfast in our commitment to pioneering innovation, accelerating clinical advancement of our core pipeline, and executing on our global partnership strategy, as we strive to deliver strong performance that upholds the trust of our shareholders."

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas. The Company is building a robust portfolio and differentiated pipeline through internal R&D capability, strategic global collaborations in co-discovery and co-development, and selective acquisitions.

Our proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. The HCAb-based Antibody Plus technology (HCAb PLUS™) provides comprehensive modality solutions for the development of innovative multi-specific medicines in different disease areas. Additionally, building upon the Harbour Mice® platform, Harbour BioMed launched its first fully human Generative AI HCAb Model powered by its Hu-mAtrIx™ AI platform, accelerating the development of innovative therapies.

By integrating Harbour Mice®, HBICE®, HCAb PLUS™, a single B-cell cloning platform and AI technologies, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com.

SOURCE Harbour BioMed

Share this article

Clover Announces Positive Phase 2 Clinical Data for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates in Older Adults

-- Positive Phase 2 (Australia) results strengthen potential best-in-class profile of RSV+hMPV±PIV3 combination vaccines, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection --

-- Robust neutralizing antibody responses across RSV, hMPV and PIV3 in Phase 2 recapitulates Phase 1 results demonstrating best-in-class breadth (with no immune interference) and no drop-off in responses in the oldest participants (75+ years) --

-- Favorable safety & tolerability profile and successful 2,000L commercial-scale production further de-risk late-stage development and commercialization --

SHANGHAI, Sept. 6, 2026 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced positive preliminary data from a Phase 2 clinical trial in older adults in Australia evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) protein-based vaccine candidates based on prefusion-stabilized F (PreF)-Trimer subunit vaccine antigens utilizing Clover's validated Trimer-Tag vaccine technology platform.

"We are pleased to announce positive Phase 2 clinical data strengthening the potential first-in-class and best-in-class profile for our RSV+hMPV±PIV3 combination vaccine candidates, with the potential differentiated ability to re-vaccinate individuals previously receiving approved RSV vaccines to restore and broaden protection," said Joshua Liang, Chief Executive Officer & Board Director of Clover. "The positive Phase 2 results significantly de-risk future late-stage development. Importantly, the results also continue to validate our differentiated Trimer-Tag platform for the development of multi-valent protein-based respiratory vaccines that have the potential to make an impact on public health and on chronic diseases caused by respiratory viruses[1]."

The ongoing Phase 2 trial for Clover's combination vaccine candidates is a randomized, observer-blinded, multi-center study with 420 older adults (60-85 years) enrolled in Australia, and the participants have been randomized to receive either SCB-1022 (RSV + hMPV), SCB-1033 (RSV + hMPV + PIV3) or placebo.

Immunogenicity

- Antibody titers (geometric mean titers [GMTs]) at 28 days post-vaccination in the Phase 2 were generally in-line with or trended higher than the prior Phase 1 trial.

- Geometric mean fold rises (GMFRs) in neutralizing antibodies (nAbs) at 28 days post-vaccination compared to pre-vaccination:

- RSV nAbs: Approximately 6-9 fold increases

- hMPV nAbs: Approximately 6-8 fold increases

- PIV3 nAbs: Greater than 3 fold increase (approximately 5 fold increase in participants with baseline PIV3 nAbs in the bottom tertile), driven by up to approximately 20 fold increases in PIV3 PreF-specific antibodies[2]

- No drop-off in antibody responses observed in the oldest participants (75+ years) compared to younger participants (60-74 years).

- No signs of immune interference on RSV and hMPV nAbs from the addition of PIV3 PreF antigen in SCB-1033 (RSV+hMPV+PIV3) compared to SCB-1022 (RSV+hMPV).

Respiratory Tract Infections (Based on AE Reporting)

- Approximately 62% lower rate of respiratory tract infection was observed in the vaccine groups (SCB-1022 and SCB-1033) versus the placebo group within 28 days of vaccination based on AE reporting of any respiratory tract infections (no PCR sequencing of infection cases was conducted in the study).

- Significant RSV outbreak[3] with co-circulation[4] of hMPV and PIV in Australia occurred during the study enrollment and follow-up period.

Safety and Reactogenicity

- SCB-1022 and SCB-1033 were generally well-tolerated; solicited local and systemic adverse events (AEs) within 7 days of vaccination were mostly mild and all transient.

- The most common solicited AEs were fatigue, headache and injection site pain, with mean durations of approximately 2 days for the vaccine groups (SCB-1022 and SCB-1033) and the placebo group.

- The frequency of unsolicited AEs within 28 days of vaccination was similar across the vaccine and placebo groups.

- There were no vaccine-related serious adverse events (SAEs), AEs of special interest (AESIs), or AEs leading to discontinuation.

Commercial-Scale Manufacturing Scale-Up

- In parallel with the Phase 2 trial, Clover conducted commercial-scale 2,000L bioreactor scale-up production of multiple batches of Trimer-Tagged RSV, hMPV and PIV3 PreF antigen components of SCB-1022/1033.

- The successful 2,000L production process scale-up further de-risk future late-stage development and commercialization.

Based on these positive Phase 2 results for the RSV + hMPV ± PIV3 combination vaccine candidates further validating the Trimer-Tag platform, Clover will continue to evaluate continued mid- and late-stage development plans as well as potential global collaboration opportunities for value maximization.

About Clover

Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable.

Clover Forward-looking Statements

This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time.

SOURCE Clover Biopharma

Share this article

Kitzbühel Tourismus triumphiert in der Kaiserlichen Hofburg

Kitzbühel (ots)

TIROLERIN Award würdigt Kitzbühels erfolgreiche Ganzjahresstrategie, Innovationskraft und regionale Wertschöpfung

Großer Erfolg für Kitzbühel Tourismus: Im festlichen Ambiente der Kaiserlichen Hofburg in Innsbruck wurde Kitzbühel Tourismus mit dem TIROLERIN Award in der Kategorie „Tourismus & Regionale Wertschöpfung“ ausgezeichnet. Geschäftsführerin Dr. Viktoria Veider-Walser nahm den Preis stellvertretend für das gesamte Team entgegen.

Über 200 Gäste aus Wirtschaft, Kultur und Politik waren zur festlichen Gala im prachtvollen Riesensaal der Hofburg gekommen. Die Auszeichnung würdigte die konsequente strategische Weiterentwicklung der Destination und ihre erfolgreiche Positionierung als attraktive Ganzjahresdestination.

In seiner Laudatio hob Florian Neuner, Bereichsleitung Branchen- und Unternehmenskommunikation bei der Tirol Werbung, insbesondere die dynamische Entwicklung von Kitzbühel Tourismus auf Basis eines konsequent verfolgten Strategieprozesses hervor. Neben dem vielfältigen Veranstaltungsangebot würdigte er die strategische Neuausrichtung, den Marken-Relaunch sowie die Stärkung und Weiterentwicklung der Marke Kitzbühel.

Einen wesentlichen Meilenstein markierte dabei der mehrfach ausgezeichnete Marken-Relaunch im Jahr 2024. Als sichtbares Ergebnis eines langjährigen Markenbildungsprozesses auf Basis von fünf definierten Erfolgsmustern, einem Leistungskern und einer klaren Positionierung bildet er die Grundlage für die langfristige Weiterentwicklung Kitzbühels als zeitgeistige Ganzjahresdestination.

Veranstaltungen als Impulsgeber für die Ganzjahresstrategie

Für Kitzbühel Tourismus ist die Auszeichnung zugleich eine Bestätigung der konsequenten strategischen Ausrichtung der vergangenen Jahre. Einen zentralen Baustein bildet dabei die ganzjährige Weiterentwicklung des Veranstaltungsangebots im B2C- und B2B-Bereich.

Kitzbühel ist seit Jahren Bühne für hochkarätige Veranstaltungen und internationale Begegnungen. Neben renommierten Sporthighlights wie den Hahnenkamm-Rennen, dem Generali Open und dem 2026 erstmals in Kitzbühel ausgetragenen Austrian Alpine Open im Rahmen der DP World Tour prägen zahlreiche weitere Veranstaltungen aus Sport, Kunst, Kultur und Lifestyle den Jahresverlauf. Dazu zählt auch die KURIER ROMY, der österreichische Film- und Fernsehpreis, die im November bereits zum zweiten Mal in der Gamsstadt gastieren wird.

„Wir sehen Veranstaltungen als Chance, hochwertige Angebote wie unser Golf-Angebot oder den Winterstart mit hochkarätigen Events wie den Austrian Alpine Open oder der KURIER ROMY Gala national und international sichtbar zu machen. Gleichzeitig ist es uns ein großes Anliegen, Lebensfreude in Kitzbühel das ganze Jahr über spürbar zu machen. Deshalb sind uns auch Formate wie der Kitzbüheler Advent oder PURA VIDA besonders wichtig. Sie zeigen, dass wir Verantwortung für unsere Destination und für alle Menschen übernehmen, die hier leben, arbeiten oder zu Gast sind“, erklärt Kitzbühel Tourismus Geschäftsführerin Dr. Viktoria Veider-Walser. Dabei betont Veider-Walser, dass dieser Erfolg nur durch das engagierte Zusammenspiel zahlreicher kompetenter und motivierter Partner aus Kitzbühel und darüber hinaus möglich wird.

Die Auszeichnung fällt zudem in ein besonderes Jubiläumsjahr: Seit dieser Woche steht Dr. Viktoria Veider-Walser seit zehn Jahren an der Spitze von Kitzbühel Tourismus.

Auch die kommenden Monate versprechen neue Impulse. Auf die Frage, was als Nächstes ansteht, bleibt Dr. Viktoria Veider-Walser noch zurückhaltend: „Something New is Coming.“ Einen Termin dürfen sich Interessierte bereits vormerken: 10. Oktober 2026.

Weitere Auszeichnung für ehrenamtliches Engagement für Tirol

Neben Kitzbühel Tourismus wurden an diesem Abend zahlreiche weitere herausragende Persönlichkeiten, Projekte und Unternehmen ausgezeichnet. Stellvertretend für alle PreisträgerInnen gratuliert Kitzbühel Tourismus Thomas Brandtner und seinem Team zur Auszeichnung in der Kategorie „Ehrenamt“ und würdigt deren Engagement für die Homebase.

Informationen zur Destination Kitzbühel finden Sie unter kitzbuehel.com

Bilder zur Veranstaltung finden Sie unter

https://kitzbuehel.px.media/share/17885194339q3t01xSM0ASNS/media

Pressekontakt:

Kitzbühel Tourismus

Mag. (FH) Anna Lena Obermoser, MA

Telefon: +43 5356 66660 16

E-Mail: a.obermoser@kitzbuehel.com

Website: presse.kitzbuehel.com

Original-Content von: Kitzbühel Tourismus, übermittelt durch news aktuell

BLUETTI stellt auf der IFA 2026 den E-Generator "Pioneer 5000" vor

Berlin (ots)

BLUETTI stellte den Pioneer 5000 vor, einen professionellen E-Generator, der für die „nächste Generation echter Arbeit" entwickelt wurde. Damit markiert das Unternehmen seinen Einstieg in den Bereich der professionellen Baustellenstromversorgung und bietet eine emissionsfreie Alternative zu herkömmlichen Kraftstoffgeneratoren.

Energieversorgung für Hochleistungswerkzeuge im Dauereinsatz

Mit einer Dauerleistung von 5 kW und einer Spitzenleistung von 18 kW versorgt der Pioneer 5000 E-Generator problemlos Geräte mit hohem Anlauf- und Spitzenstrombedarf wie Bohrmaschinen, Trennsägen, Luftkompressoren und Wasserpumpen mit Strom. Die 5,12-kWh-LiFePO₄-Batterie lässt sich auf eine Kapazität von bis zu 35 kWh erweitern und ermöglicht so einen zuverlässigen und langanhaltenden netzunabhängigen Betrieb.

Entwickelt für anspruchsvolle Einsatzbedingungen

Der Pioneer 5000 E-Generator überzeugt nicht nur durch seine Leistung, sondern auch durch seine Zuverlässigkeit bei Regen, Staub und unebenem Gelände. Dafür sorgen die Schutzklasse IP65, die Stoßfestigkeit nach IK10, ein robuster Rahmen sowie geländegängige Räder. Darüber hinaus ist das Gerät für einen zuverlässigen Betrieb bei extremen Temperaturen von -20 °C bis 55 °C ausgelegt.

Sauberere und leisere Energieversorgung

Im Vergleich zu Kraftstoffgeneratoren verursacht der Pioneer 5000 E-Generator keinerlei Abgasemissionen, arbeitet mit einem Geräuschpegel von ≤50 dB und macht regelmäßiges Betanken sowie die typische Wartung eines Verbrennungsmotors überflüssig, sodass er in Innenräumen, nachts und in lärmempfindlichen Umgebungen eingesetzt werden kann. Der Pioneer 5000 ermöglicht damit einen saubereren und leiseren Betrieb bei gleichzeitig geringerem Wartungsaufwand und setzt neue Maßstäbe für professionelle Stromversorgung.

Schnelle und flexible Energiezufuhr

Der Pioneer 5000 E-Generator unterstützt AC-Schnellladen und kann in nur 60 Minuten von 5 % auf 80 % geladen werden. Darüber hinaus stehen verschiedene Lademöglichkeiten zur Verfügung, darunter Solar-PV, das Laden über ein Fahrzeug sowie über einen Kraftstoffgenerator.

Für einen längeren netzunabhängigen Betrieb verfügt das System über eine integrierte DO-Schnittstelle, die den intelligenten automatischen Start und Stopp eines angeschlossenen Kraftstoffgenerators ermöglicht. Dieser wird dadurch nur bei Bedarf aktiviert, um den Kraftstoffverbrauch, den Motorverschleiß und die Wartungskosten zu senken.

Vernetzte und zentral verwaltbare Energieversorgung

Das System kombiniert professionelle Stromanschlüsse mit einer USV-Umschaltung innerhalb von 10 ms sowie optionaler 4G-Konnektivität und ermöglicht damit Fernüberwachung, Leistungssteuerung, Standortverfolgung und Diebstahlschutz. Damit entwickelt sich die mobile Stromversorgung von einem klassischen Einzelgerät zu einer vernetzten und intelligent verwaltbaren Energielösung.

Diese Funktionen helfen professionellen Anwendern dabei, Ausfallzeiten und Betriebskosten zu minimieren und gleichzeitig eine hohe Produktivität im täglichen Einsatz sicherzustellen.

Besuchen Sie BLUETTI auf der IFA Berlin 2026

Datum: 4. bis 8. September 2026

Stand: Halle 2.2, Stand 176, Messe Berlin, Deutschland

Über BLUETTI

Seit 2013 ist BLUETTI ein technologischer Vorreiter im Bereich der sauberen Energie und bietet maßgeschneiderte Stromversorgungslösungen für Privathaushalte sowie für gewerbliche und industrielle Anwendungen.

Mit eigener Forschung und Entwicklung, eigener Fertigung und einem kontinuierlich wachsenden Patentportfolio setzt BLUETTI in der Branche immer wieder neue Maßstäbe in Sachen Leistung, Sicherheit und Nachhaltigkeit. Heute vertrauen mehr als 3,5 Millionen Nutzer in über 120 Ländern auf die Energielösungen von BLUETTI.

Pressekontakt:

Carol Gu, Integrierte Marketingkommunikation, gujiarong@bluetti.com

Original-Content von: BLUETTI, übermittelt durch news aktuell

TGI Fridays™ Signs Landmark Development Agreement with Devolli Group, Accelerating Global Growth with First-Ever Expansion into the Balkans

Plans include 10 restaurants across Kosovo, Albania and North Macedonia, establishing a strategic gateway for growth across Southeast Europe and reinforcing TGI Fridays' global expansion under its 1-2-3 Strategic Vision.

DALLAS, Sept. 4, 2026 /PRNewswire/ -- TGI Fridays™, the iconic global restaurant and bar brand, today announced the signing of a landmark development agreement with Devolli Group, one of the Balkans' leading diversified business groups, marking the brand's first-ever expansion into Kosovo, Albania and North Macedonia.

The agreement represents a significant milestone in TGI Fridays' international growth strategy and reinforces the brand's global momentum as it continues to scale through its franchise-first development model. As part of the partnership, Devolli Group will develop 10 TGI Fridays™ restaurants across the three markets and has secured exclusive rights to sub-franchise the brand throughout the territory, creating a platform for long-term expansion across Southeast Europe. The partnership lays the foundation for long-term growth across the Balkans, bringing TGI Fridays'™ bar-forward atmosphere, bold and craveable menu, and high-energy dining experience to guests across Kosovo, Albania and North Macedonia.

This development agreement is the latest milestone in TGI Fridays'™ ambitious 1-2-3 Strategic Vision to operate more than 1,000 restaurants worldwide by 2030. Over the past nine months alone, TGI Fridays™ has accelerated its international expansion by signing new development agreements in Kenya and the Maldives, while extending strategic partnerships to drive continued growth across Peru, Japan, Mexico, the Philippines, Greece, Cyprus and Spain. Collectively, these agreements have added more than 150 restaurants to the brand's global development pipeline, reinforcing the strength of TGI Fridays'™ international franchise network and demonstrating the continued global demand for one of the world's most iconic casual dining brands.

For more than 60 years, TGI Fridays™ has been bringing people together through great food, handcrafted drinks and unforgettable celebrations. The Balkans, with its rich tradition of hospitality, vibrant social culture and strong sense of community, represents a natural next chapter for the brand's international growth.

As one of Europe's fastest-growing tourism and hospitality regions, fueled by increasing international investment, modern retail developments and evolving consumer demand, the Balkans presents an exciting opportunity to introduce the iconic TGI Fridays™ experience to a new generation of guests across Kosovo, Albania and North Macedonia. Beyond expanding consumer choice, the partnership is expected to create new employment opportunities, invest in local hospitality talent and contribute to the continued growth of the region's foodservice, tourism and visitor economy while bringing the unmistakable Fridays spirit to one of Europe's most dynamic emerging markets.

"The Balkans represent one of Europe's most exciting growth opportunities, combining entrepreneurial energy, a thriving hospitality sector and a culture that values gathering around the table. Those qualities align perfectly with what TGI Fridays™ has stood for since day one," said Phil Broad, Global President, TGI Fridays™. "Devolli Group is the right partner to introduce TGI Fridays™ to the Balkans. Their market expertise, operational excellence and long-term vision give us tremendous confidence in what we can build together. This partnership not only expands our international footprint, but also advances our 1-2-3 Strategic Vision as we continue bringing the Fridays experience to new guests around the world."

Blerim Devolli, President of Devolli Group, added:

"We are proud to bring TGI Fridays, one of the world's most recognized American casual dining restaurant brands, to Albania, Kosovo, and North Macedonia. This partnership reflects our commitment to investing in world-class brands and delivering exceptional hospitality experiences across the region. We look forward to building a strong, long-term business that creates new opportunities, develops local talent, and brings a globally recognized dining experience to our customers and communities."

The addition of the Balkans further strengthens TGI Fridays'™ European footprint, complementing its established operations in Greece, Cyprus, Spain, Norway and the United Kingdom. The agreement reflects the continued momentum of TGI Fridays'™ franchise-first growth strategy, expanding into high-potential markets through experienced local partners. Guided by its "1-2-3 Strategic Vision," the brand remains focused on accelerating global expansion while delivering the iconic Fridays experience with consistency, quality and local relevance.

As TGI Fridays™ enters the Balkans for the first time, the partnership with Devolli Group marks more than expansion into a new region, it begins a long-term commitment to investing in local communities, creating opportunities and bringing the unmistakable Fridays spirit to a new generation of guests across Southeast Europe. Because wherever TGI Fridays goes, every day should feel a little more like Friday.

For more information: www.tgifridays.com/franchise/

About TGI Fridays™

Founded in 1965 as the world's first casual bar and grill, TGI Fridays™ is where the world goes to celebrate. Operating nearly 400 restaurants in almost 40 countries, Fridays™ brings people together through its craveable American classics, legendary cocktails and that unmistakable Fridays™ feeling - all brought to life by its rockstar teams. Whether it's full-service dining or bold-format convenience, TGI Fridays™ franchise-first approach, operational excellence, and brand power are built to scale. Franchisees are supported by global hubs in Dallas, Dubai and London, complemented by regional resources in select markets. Visit www.tgifridays.com for more information, join Fridays Rewards, and follow TGI Fridays™ on social media: Instagram @tgifridays, Tik Tok @tgifridays, Facebook TGI Fridays, and LinkedIn TGI Fridays.

About Devolli Group

Devolli Group is one of the largest privately owned business groups in Southeast Europe, with a diversified portfolio spanning manufacturing, food and beverage production, hospitality, retail, real estate, and strategic investments. Headquartered in Kosovo, the Group operates across multiple international markets and employs thousands of people throughout the region.

With a strong focus on innovation, quality, and long-term sustainable growth, Devolli Group has developed a portfolio of leading regional brands while successfully partnering with globally recognized companies. Through continuous investment in modern technology, people, and international expansion, the Group remains committed to creating lasting value for customers, business partners, local communities, and the economies in which it operates.

Devolli Group continues to expand its international partnerships, bringing globally recognized brands and world-class business concepts to Albania, Kosovo, North Macedonia, and the wider region.

Media Contact:

Share this article

BROOMFIELD, Colo., Sept. 4, 2026 /PRNewswire/ -- Vail Resorts, Inc. (NYSE: MTN) announced today it will release the Company's financial results for its fourth quarter and fiscal year ended July 31, 2026 after market close on Monday, September 28, 2026. The Company will host a conference call at 5:00 p.m. Eastern Time that same day during which Company executives will review the financial results.

The call will be broadcast at investors.vailresorts.com. Those wishing to participate via telephone should dial (800) 225-9448 to be connected. Callers outside of the U.S. or Canada should dial +1 (203) 518-9708. The conference ID is MTNQ426.

In addition, a replay of the call will be available two hours following the conclusion of the conference call through October 5, 2026. To access the replay, dial (800) 753-0348 (U.S. and Canada) or +1 (402) 220-2672 (international). The call also will be archived at investors.vailresorts.com.

About Vail Resorts, Inc. (NYSE: MTN)

Vail Resorts is a network of the best destination and close-to-home ski resorts in the world including Vail Mountain, Breckenridge, Park City Mountain, Whistler Blackcomb, Stowe, and 32 additional resorts across North America; Andermatt-Sedrun and Crans-Montana Mountain Resort in Switzerland; and Perisher, Hotham, and Falls Creek in Australia - all available on the company's industry-changing Epic Pass. We are passionate about providing an Experience of a Lifetime to our team members and guests, and our EpicPromise is to reach a zero net operating footprint by 2030, support our employees and communities, and broaden engagement in our sport. Our company owns and/or manages a collection of elegant hotels under the RockResorts brand, a portfolio of vacation rentals, condominiums and branded hotels located in close proximity to our mountain destinations, as well as the Grand Teton Lodge Company in Jackson Hole, Wyo. Vail Resorts Retail operates more than 250 retail and rental locations across North America. Learn more about our company at www.VailResorts.com, or discover our resorts and Pass options at www.EpicPass.com.

SOURCE Vail Resorts, Inc.

Share this article